Refine by
Bladder Cancer Patient Suppliers & Manufacturers
5 companies found
based inDunedin,, NEW ZEALAND
Pacific Edge is a cancer diagnostics company. We specialise in discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer. Our ...
Cxbladder is a non-invasive genomic urine test that quickly and accurately detects or rules out bladder cancer. The tests works at a molecular level, measuring five biomarker genes to detect the presence or absence ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Decipher Bladder is the only genomic subtyping tool available to physicians in the United States treating patients with locally advanced bladder ...
based inIrvine, CALIFORNIA (USA)
Established in 2011, Pathnostics is driven to pioneer a better future for physicians, patients, and the healthcare system with solutions that transform diagnostic and therapeutic dilemmas. Core capabilities in infectious disease and cancer ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib ...
based inNew York, NEW YORK (USA)
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies ...
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). TARA-002 was developed from the same master cell bank of genetically distinct group A ...